Beynon Sports Elevates Its World-Class Manufacturing With ISO 14001 Certification
Recognition highlights an industry-leading push towards sustainability and eco-friendly manufacturing
HUNT VALLEY, MARYLAND / ACCESS Newswire / February 24, 2025 / Beynon Sports, a global leader in high-performance track and field surfacing, announced today that it has been awarded ISO 14001 certification, the internationally recognized standard for environmental management systems (EMS). This milestone underscores Beynon's ongoing commitment to sustainability and responsible business practices, which have earned the trust of renowned track and field programs, world-class venues, and municipalities across the globe.
The ISO 14001 certification demonstrates the company's adherence to operational standards that minimize environmental impact while maintaining superior quality and safety. Beynon's eco-friendly manufacturing processes complement the development of high-performance, durable surfaces that support athletes and communities worldwide.
This recognition of Beynon Sports' industry-leading environmental stewardship follows the recent reissuing of the company's ISO 9001 certification. Beynon has held its ISO 9001 certification, a globally recognized standard for quality management, since February 2015.
Every Beynon track is produced at its advanced manufacturing facility in Hunt Valley, Maryland. The reputation of the facility-already one of the few in the industry to have its Quality Management Systems certified to ISO 9001-is further bolstered by its new ISO 14001 status.
'We are proud to add ISO 14001 to our certifications, alongside ISO 9001, reinforcing our team's focus on responsible manufacturing and environmental best practices,' said Michael Gasparovic, VP of Plant Operations and R&D, Beynon Sports. 'Sustainability is not just a priority-it's an integral part of how we operate, innovate, and deliver world-class surfaces for athletes.'
A Track Record of Sustainability
The certifications are part of Beynon's long track record of achieving the highest industry standards in its manufacturing process and corresponding products.
In June 2020, 14 Beynon track systems obtained GreenGuard Gold certification -the highest level available through the leading program committed to global sustainability, environmental health, and safety. Then, in 2022, eight Beynon products received USDA BioPreferred® Certification.
Last year, Beynon earned the U.S. Department of Agriculture (USDA) Certified Biobased Product Label for its BEYPUR™ 320-Bio and BEYPUR™ 340-Bio polyurethane binder products. The label highlights Beynon's commitment to sustainability while providing customers with a verified indicator of its products' renewable, biobased materials.
###
About Beynon Sports
Beynon Sports, a Tarkett Sports Company, is a leading manufacturer of high-performance athletic surfaces, specializing in the design and installation of durable, resilient track and field solutions. With over 40 years of experience, the company is renowned for its innovative technology and commitment to quality. Beynon's indoor and outdoor products are designed to meet the needs of professional athletes, educational institutions, and sports organizations worldwide.
Their expertise has been trusted at over 7,500 locations in North America, including prominent venues:
The University of Oregon (Hayward Field), the TRACK at new balance, The Podium Powered by STCU (Spokane, WA), the University of Kentucky, Texas A&M, the University of Texas at San Antonio, Auburn University, Boston University, Ohio State University, and many more.
About Tarkett Sports
Leading solutions delivered by leading builders. Tarkett Sports is a world leader in sports construction and surfacing. Providing architectural design, full-scope construction services, and a comprehensive portfolio of industry-leading sports surfacing solutions, Tarkett Sports delivers a seamless turnkey experience for its clients.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
Securonix Acquires ThreatQuotient to Deliver Industry's Broadest and Deepest Threat Detection Investigation and Response
PLANO, Texas--(BUSINESS WIRE)--Today, Securonix, a five-time Leader in the Gartner® Magic Quadrant™ for Security Information and Event Management (SIEM), announced the acquisition of ThreatQuotient, a four-time leader in threat intelligence based on QKS Group Spark Matrix report and the force behind ThreatQ, the most innovative external threat intelligence platform. This combination will create a comprehensive, modular, and fully integrated AI-driven platform for threat detection, investigation, and response (TDIR), leveraging advanced analytics and insights across both internal and external threats. This acquisition accelerates the modernization of security operations by uniting internal and external threat intelligence with real-time analytics and agentic AI. Unlike external threat intelligence bolt-on solutions with disconnected management interfaces, the integrated platform from Securonix and ThreatQuotient will deliver unified visibility, faster response, and greater operational clarity. "Bringing threat intelligence management and SIEM together in a unified platform is a game changer. We've already seen the value of deeply enriched advanced analytics and detection in our Securonix SIEM environment—but coupling that with integrated threat curation, prioritization, and response should help customers move even faster. It means fewer swivel-chair investigations, more accurate triage, and greater confidence that security analysts are working with the most relevant threats. This kind of integration has the potential to accelerate the ability to detect, respond, and stay ahead," said Marcel Jonker, Director of Cybersecurity Operations at Cambia Health Systems. The integration of Securonix and ThreatQuotient promises to deliver up to a 70% reduction in Mean Time to Respond (MTTR), enabling security teams to detect, investigate, and remediate threats significantly faster. By combining curated threat intelligence with AI-driven automation, the solution will deliver exponential improvements in filtering out false positives, enriching alerts with actionable context, and automating historical threat sweeps and incident response. This reduces alert overload, speeds up root cause analysis, and minimizes manual handoffs—cutting investigation time from hours to minutes and enabling automated containment before threats escalate. 'Security teams are drowning in noise and struggling to keep up with evolving threats,' said Kash Shaikh, CEO and President of Securonix. 'This acquisition brings together Securonix's Agentic AI-driven Platform with ThreatQuotient's deep threat intelligence to deliver clarity, speed, and automated workflows to our customers, reducing false positives by up to 90%. Together, we're building the modern SOC Platform—proactive, intelligent, and built for what's next.' Kash added, 'Securonix and ThreatQuotient bring together complementary strengths—deep innovation across internal and external threat domains, and a shared commitment to innovation and customer service. Both companies serve enterprise and government customers as well as managed security service providers (MSSPs), and we're excited to welcome the talented ThreatQuotient team and their customers to Securonix.' Purpose-Built for Analysts. Proven Against Real-World Threats. ThreatQuotient's Threat Intelligence Platform (TIP) strength lies in delivering curated, contextualized threat intelligence that drives smart, timely decisions. When combined with Securonix's EON Agentic AI-based SIEM, SOAR, UEBA and Data Pipeline Manager, customers can accelerate their migration from reactive threat hunting-based defense to proactive, real-time, behavior-driven, open-agentic security operations. With this integration, Securonix customers and partners will enjoy the following benefits: Gain clear visibility: Integrate deep enriched real-time analytics from Securonix with curated external intelligence from ThreatQuotient to create a single, high-context stream of alerts. Eliminate blind spots and accelerate threat identification with confidence. Stay ahead of risk: Auto-enrich Indicator of compromise (IoCs) and preemptively respond to repeat attacks, blocking 90 percent before they start. Act smarter: Automate repetitive tasks, reduce false positives, and streamline investigations. Teams can stay focused on high-priority threats and reduce time spent on manual triage. Deploy your way: Continue to use ThreatQ as a standalone threat intelligence platform or as part of the fully integrated Securonix solution. Deploy on-premise or SaaS in a way that fits the current architecture and scales with needs. Accelerated Roadmap: Combined R&D synergies will accelerate upcoming roadmap innovations, including Agentic AI and ThreatQuotient's innovation priorities. With this acquisition, ThreatQuotient customers and partners will enjoy the following benefits: Increased Scale: ThreatQ customers can take advantage of Securonix's global R&D scale and GTM reach, including access to Securonix's Threat Labs Intelligence. Deeper Integrations: Gain access to an enriched roadmap and integration between Securonix's best-in-class SIEM, SOAR, and UEBA portfolio and ThreatQ, including extension of Agentic AI advancements. Continued Focus: Zero interruption of their existing service, as ThreatQuotient will continue to operate as a standalone offering, with no disruption to existing roadmap and workflows. 'Enterprises, government institutions and managed security service providers rely on ThreatQuotient to protect their mission critical businesses. Joining Securonix marks a powerful new chapter for ThreatQuotient. By uniting our strengths, we can accelerate innovation, expand our reach, and deliver greater value to our customers. I'm proud of what we've built and excited for what's ahead,' said John Czupak, CEO of ThreatQuotient. BTIG, LLC served as exclusive financial advisor, and King & Spalding LLP served as legal advisor to ThreatQuotient. Vinson & Elkins LLP served as legal advisor to Securonix. About Securonix Securonix is leading the transformation of cybersecurity with the industry's first Unified Defense SIEM powered by agentic AI, purpose-built to decide and act across the threat lifecycle with a human-in-the-loop philosophy. Built for scale, precision, and speed, our cloud-native platform empowers global enterprises to shift from reactive security to proactive, autonomous operations. Recognized as a Leader in the Gartner® Magic Quadrant™ for SIEM and a Customers' Choice by Gartner Peer Insights™, Securonix is driving the next era of intelligent, autonomous security operations. Learn more at About ThreatQuotient ThreatQuotient improves security operations by fusing disparate data sources, tools, and teams to accelerate threat detection, investigation, and response (TDIR). ThreatQ is the first purpose-built, data-driven threat intelligence platform that helps teams prioritize, automate, and collaborate on security incidents; enables more focused decision-making; and maximizes limited resources by integrating existing processes and technologies into a unified workspace. The result is reduced noise, clear priority threats, and the ability to automate processes with high-fidelity data. ThreatQuotient's leading integration marketplace, data management, orchestration, and automation capabilities support multiple use cases including threat intelligence management and sharing, incident response, threat hunting, spear phishing, alert triage, and vulnerability management. For more information, visit
Yahoo
6 hours ago
- Yahoo
Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego
- Engaged with FDA Commissioner on shared commitment to fast, safe, and affordable patient access to innovative therapies SAN DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it was selected by the U.S. Food and Drug Administration (FDA) to participate in the FDA CEO Forum in San Diego, California, on June 13, 2025. Minami Maeda, President of Rakuten Medical, attended the meeting in person as a member of this panel, to discuss with FDA Commissioner Marty A. Makary, M.D., M.P.H., and other industry leaders how the FDA can "modernize its regulatory framework to better support innovation and patient access to safe and effective therapies". Rakuten Medical – whose innovative cancer therapeutic technology, the Alluminox™ platform, is in Phase 3 trials in the U. S. – was selected to join the forum as one of the companies at the front lines of medical discovery. Rakuten Medical's novel treatment modality, known as photoimmunotherapy, is designed to induce rapid and selective depletion of cancer or immunosuppressive cells with minimal impact on surrounding healthy tissue. Moreover, pre-clinical observation have shown that photoimmunotherapy may also stimulate both innate and adaptive anti-tumor immune responses. "Rakuten Medical's Alluminox™ platform has the potential to transform cancer therapy in the U.S.," said Maeda. "We are honored to be recognized by the FDA and invited to contribute to discussions on how regulatory innovation can accelerate the delivery of pioneering treatments to patients. We fully support the FDA's vision of a modern framework that ensures timely access, safety, and affordability." Rakuten Medical is currently conducting a global Phase 3 clinical trial evaluating its ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line treatment for patients with recurrent head and neck squamous cell carcinoma (HNSCC) (Protocol number: ASP-1929-381 / Acronym: ECLIPSE / Identifier: NCT06699212). A prior Phase 1b/2 study showed promising interim evaluation results, including a 24-month survival rate of 52.4% and a median overall survival (OS) not yet reached. ASP-1929 photoimmunotherapy received the world's first regulatory approval in Japan under the Conditional Early Approval System based on a certain level of efficacy and acceptable safety from Phase 1/2a trial results. It is being delivered to patients in Japan at an affordable price. Disclaimer: Rakuten Medical's Alluminox™ platform-based photoimmunotherapy is investigational outside Japan. About Rakuten Medical, Inc. Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical's photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit About Alluminox™ platform The Alluminox™ platform is Rakuten Medical's investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical's pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical's Alluminox platform-based photoimmunotherapy is investigational. About ASP-1929Rakuten Medical's first pipeline drug developed on its Alluminox™ platform is ASP-1929, an antibody-dye conjugate comprised of the anti-EGFR antibody cetuximab and IRDye® 700DX, a light activatable dye. ASP-1929 binds to epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority. Contact Us View original content to download multimedia: SOURCE Rakuten Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
EPA proposes historic renewable fuel blending standards
U.S. Secretary of Agriculture Brooke Rollins at an ethanol production facility in Atlantic. (Photo by Cecilia Lynch/USDA) The U.S. Environmental Protection Agency Friday released its renewable fuel standards draft rule which, if finalized, would set record high levels of biofuels to be blended into U.S. transportation fuels. Iowa Renewable Fuels Association Executive Director Monte Shaw said the draft rule, which proposes a total 24.02 billion gallon blending level in 2026, is a 'very strong starting point for further discussions.' Shaw said the association will need time to evaluate the proposal, specifically as it relates to changes in credits for imported fuels and feedstocks. According to the proposal, EPA is considering 'several regulatory changes' to the RFS program that would reduce the number of Renewable Identification Numbers, or RINs which is the measuring unit for renewable fuel, for imported renewable fuels and renewable fuels produced from imported feedstocks. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX The U.S. Department of Agriculture reports imported biodiesel feedstocks, like used cooking oil, tallow and canola oil have all increased over the past several years due to the high cost of domestic feedstocks. According to the same report, in the 2023 and 2024 marketing year, the U.S. consumed nearly 30% of biofuel feedstocks exported globally. The news to prioritize domestic feedstocks was welcomed by Iowa Soybean Association President Brent Swart, who said biomass-based diesel supports 'roughly 10% of the price per bushel of soybeans.' 'Biomass-based diesel has long provided significant value to soybean farmers, helping us weather difficult economic times and supporting our state's thriving agriculture industry,' Swart said in a statement. The EPA program sets overall standards and specific standards for different types of biofuels. The draft rules propose biomass-based diesel standards equivalent to 5.61 billion gallons in 2026 and 5.86 billion gallons in 2027. These figures are a significant jump from 2025 targets from EPA, which set an annual volume requirement of 3.35 billion gallons for biomass-based diesel. 'This is a significant step toward putting the market back on track,' Swart said. 'It is also a long overdue recognition that Iowa farmers, soybean processors and the state's biodiesel producers, can contribute even more (to) America's energy output.' Swart said the announcement 'provides added certainty' for soybean farmers during the growing season and he thanked the Trump administration for supporting 'farmers' critical role' in U.S. energy policy. U.S. Secretary of Agriculture Brooke Rollins said USDA and EPA have 'never been more aligned' on the demand for domestically grown biofuels. 'This is the highest ever Renewable Volume Obligation and it sends a strong signal to the U.S. biofuels industry that President Trump has their backs and gives them the incentive to invest in American products for American consumers and to export around the world,' Rollins said in a statement. Iowa is the leading producer of biofuels in the nation. According to Iowa Soybean Association, the soybean oil used to produce biodiesel in Iowa in 2024 was equivalent to more than 30% of the soybeans grown in the state. An IRFA report found that in 2024, the state produced 4.61 billion gallons of fuel ethanol, and the industry provided a market for nearly 60% of Iowa's 2024 corn crop. The same study, however, showed a decline in economic impact from the biofuels industry, and IRFA said entry to the ultra-low carbon fuel market would be the 'most cost-effective and impactful' way to revitalize biofuels and corn markets. The EPA proposal additionally waives the 2025 cellulosic biofuel volume requirement and reinstates the values through 2026 and 2027, due to a shortfall in the production of the fuels made from nonfood-based renewable feedstocks, like cellulose or lignin. The draft rule also removes renewable electricity as a qualifying renewable fuel under the program, which follows a move from the Trump administration to block state-specific mandates on emissions that encouraged the use of electric vehicles. U.S. Sen. Joni Ernst celebrated the move and the EPA announcement in a statement, saying it brings RFS 'back on track.' 'By eliminating the electric vehicle mandate and restoring the RFS' original focus on liquid transportation fuels, prioritizing domestically grown crops over foreign imports, setting record-high volumes to revitalize the biofuel industry, and adopting safeguards to prevent small refinery waivers from gutting the program—it is clear the Trump administration is committed to championing rural America,' Ernst said. Iowa Secretary of Agriculture Mike Naig similarly applauded the move, including the proposed regulation changes to steer producers away from foreign-made feedstocks. 'President Trump is once again demonstrating his commitment to showcasing how Iowa-made biofuels can be central to his effort to make America energy dominant,' Naig said in a statement. 'Biofuels are a win for drivers and American farmers – they save drivers money at the pump, directly support corn and soybean prices, expand markets for farmers, and support rural jobs and communities.' EPA will host a public hearing on the rules July 8. Shaw said IRFA plans to work with EPA through the commenting period and to secure a final rule from the agency. 'Agriculture is hurting, having just endured the largest two-year drop in net farm income in history,' Shaw said. 'We need forward leaning RFS blending levels to maximize American energy dominance.' SUPPORT: YOU MAKE OUR WORK POSSIBLE
